What is HC Wainwright’s Estimate for Femasys Q1 Earnings?

Femasys Inc. (NASDAQ:FEMY) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Femasys in a report released on Tuesday, February 11th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.23) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Femasys’ Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.14) EPS and FY2029 earnings at $0.01 EPS.

Separately, Chardan Capital dropped their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Femasys Price Performance

Shares of NASDAQ:FEMY opened at $1.38 on Thursday. The company’s 50-day moving average is $1.14 and its 200 day moving average is $1.12. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The company has a market capitalization of $31.60 million, a P/E ratio of -1.70 and a beta of -2.81. Femasys has a fifty-two week low of $0.86 and a fifty-two week high of $2.40.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aljian Capital Management LLC bought a new position in Femasys in the third quarter worth $27,000. Virtu Financial LLC bought a new position in Femasys in the fourth quarter worth $25,000. XTX Topco Ltd raised its holdings in Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after purchasing an additional 17,473 shares in the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.